Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant S-1 and Radiotherapy for Borderline Resectable Pancreatic Cancer
NCT02459652Phase 2Completed
- Sponsor
- Japan Adjuvant Study Group of Pancreatic Cancer
- Start
- Dec 2012
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tegafur in pancreatic ductal adenocarcinoma (PDAC), sponsored by Japan Adjuvant Study Group of Pancreatic Cancer. Started Dec 2012; status: completed.
02
Drugs
tegafur
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02459652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02459652.